During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation by Cohen, Shenhav et al.
JCB: ARTICLE
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 185 No. 6  1083–1095
www.jcb.org/cgi/doi/10.1083/jcb.200901052 JCB 1083
Correspondence to Alfred L. Goldberg: alfred_goldberg@hms.harvard.edu
Abbreviations used in this paper: MyBP-C, myosin-binding protein C; MyHC, 
myosin heavy chain; MyLC, myosin light chain; MuRF, muscle RING-finger; WT, 
wild type.
Introduction
Atrophy of skeletal muscle occurs upon disuse or denervation 
and systemically in fasting and many disease states, including 
cancer cachexia, sepsis, renal failure, and cardiac failure (Lecker 
et al., 1999, 2006; Jackman and Kandarian, 2004). This rapid 
loss of muscle mass is largely due to accelerated protein degrada-
tion, although in systemic catabolic states protein synthesis also 
decreases (Jackman and Kandarian, 2004; Lecker et al., 2006; 
Sacheck  et  al.,  2007).  Normally,  the  proteins  comprising  the 
myofibril are among the most stable in the body. During atrophy, 
however, the myofibrillar apparatus, which comprises at least 
60% of muscle proteins, decreases in mass to a greater extent 
than the soluble components (Munoz et al., 1993) and results in 
decreased strength. The present studies were undertaken to gain 
insight into the mechanisms responsible for this accelerated deg-
radation of myofibrillar proteins.
Recent findings indicate that these different types of atro-
phy activate a common series of biochemical and transcriptional 
adaptations (Sacheck et al., 2007) leading to enhanced pro-
tein degradation by both proteasomal and lysosomal systems 
(Mammucari et al., 2007; Zhao et al., 2007). The degradation of 
myofibrillar components during atrophy is mediated by the 
ubiquitin–proteasome pathway (Solomon and Goldberg, 1996). 
Despite this rapid degradation of diverse muscle proteins dur-
ing atrophy, two muscle-specific ubiquitin ligases (E3s), muscle 
RING-finger 1 (MuRF1) and atrogin-1/MAFbx, are markedly 
induced; and in knockout mice lacking either enzyme, the rapid 
loss of muscle mass upon denervation is significantly reduced 
(Bodine et al., 2001; Gomes et al., 2001). To date, it is unclear 
whether these E3s ubiquitylate many muscle components or 
only key regulatory ones, whose destruction promotes the break-
down of other proteins. MuRF1 is a monomeric E3 belonging 
to the tripartite motif family of ligases which contain a tripartite 
RING:B-box:coiled-coil domain that is essential for ubiquitin 
conjugation. Two close homologues of MuRF1 (MuRF2 and 
L
oss of myofibrillar proteins is a hallmark of atro-
phying muscle. Expression of muscle RING-finger 1 
(MuRF1), a ubiquitin ligase, is markedly induced 
during atrophy, and MuRF1 deletion attenuates muscle 
wasting. We generated mice expressing a Ring-deletion 
mutant MuRF1, which binds but cannot ubiquitylate sub-
strates. Mass spectrometry of the bound proteins in de-
nervated muscle identified many myofibrillar components. 
Upon denervation or fasting, atrophying muscles show 
a loss of myosin-binding protein C (MyBP-C) and myo-
sin light chains 1 and 2 (MyLC1 and MyLC2) from the 
myofibril,  before  any  measurable  decrease  in  myosin 
heavy chain (MyHC). Their selective loss requires MuRF1. 
MyHC is protected from ubiquitylation in myofibrils by 
associated proteins, but eventually undergoes MuRF1-
dependent degradation. In contrast, MuRF1 ubiquitylates 
MyBP-C, MyLC1, and MyLC2, even in myofibrils. Because 
these proteins stabilize the thick filament, their selective 
ubiquitylation  may  facilitate  thick  filament  disassembly. 
However, the thin filament components decreased by a 
mechanism not requiring MuRF1.
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stability, their selective loss and rapid ubiquitylation, which we 
demonstrate here, are likely to be a mechanism promoting myo-
fibrillar disassembly during atrophy.
In these studies, we used biochemical and genetic ap-
proaches to clarify in vivo the contribution of MuRF1’s ligase 
activity to the atrophic process and to clarify MuRF1’s role in 
disassembly of the myofibrillar apparatus in adult mice. Specifi-
cally, we investigated (1) whether any myofibrillar protein may 
be lost selectively during denervation atrophy, (2) whether ubiq-
uitylation by MuRF1 is important for the degradation of the vari-
ous myofibrillar proteins lost during atrophy, (3) whether MuRF1 
can ubiquitylate regulatory proteins, whose loss may promote the 
breakdown of other myofibrillar components, and (4) whether 
myofibrillar proteins that are degraded in a MuRF1-dependent 
mechanism can be ubiquitylated within the myofibril, in the 
extracted actomyosin complex, or only when isolated and purified. 
These studies surprisingly demonstrate that distinct mechanisms 
exist for degrading components of the thick and thin filaments, 
and that certain thick filament–associated proteins are lost differ-
entially during atrophy and are selectively ubiquitylated within 
the intact myofibril. Their differential loss may represent a criti-
cal step that promotes further ubiquitylation and degradation of 
other myofibrillar components.
Results
MuRF1 binds a specific subset of  
muscle proteins
To understand the role of MuRF1 in muscle atrophy, we sought 
to  identify  its  substrates.  Soluble  extracts  of  gastrocnemius 
muscles from normal mice (the 3,000 g supernatant) were incu-
bated with immobilized GST-MuRF1 to isolate those muscle 
proteins having high affinity for MuRF1. The resulting precipi-
tates were washed extensively with buffer containing 500 mM 
NaCl to remove nonspecific or weakly associated proteins. The 
proteins on the pellets were analyzed by SDS-PAGE (Fig. S1) 
and mass spectrometry. Many myofibrillar components, espe-
cially components of the thick filaments and M-line region, 
were identified (Table I), including myosin-binding protein C 
(MyBP-C, also called C-protein), myosin essential light chain 
(MyLC1) and regulatory light chain (MyLC2), myosin heavy 
chain (MyHC) type II isoform, myomesin 1, and filamin C (also 
called filamin 2, -filamin, or ABP-L), a component localized 
to the Z-disk. This binding of MyLC2 is consistent with the re-
sults of screening a muscle cDNA library for MuRF1-binding 
proteins by a yeast two-hybrid assay (Witt et al., 2005). Further-
more, MyHC (Clarke et al., 2007) has been shown to be ubiqui-
tylated by purified MuRF1. We could not precipitate Troponin-I 
from skeletal muscle extracts with MuRF1, although cardiac 
Troponin-I is reported to be a substrate of MuRF1 in vivo 
(Kedar et al., 2004), and is readily ubiquitylated by purified 
MuRF1 (Kim et al., 2007).
To confirm that these MuRF1-binding proteins (Table I) 
are indeed potential substrates, we repeated the isolation of   
proteins  together  with  purified  GST-MuRF1  from  normal   
gastrocnemius muscles and subsequently tested if these bound 
components could be ubiquitylated after addition of E1, UbcH1, 
MuRF3) are present in normal muscle and appear to be impor-
tant for maintenance of normal contractile function (Fielitz 
et al., 2007; Witt et al., 2008). MuRF1, on the other hand, is 
required for rapid atrophy but not for normal muscle growth.
In  the  present  studies,  we  have  used  mice  that  lack 
MuRF1’s RING domain to clarify the role of its ligase activity 
in denervation atrophy. Although two substrates have been 
reported for MuRF1, cardiac Troponin-I (Kedar et al., 2004) 
and myosin heavy chain (MyHC) (Clarke et al., 2007), the role 
of MuRF1 in degrading specific myofibrillar or soluble proteins 
in skeletal muscle is unknown. Specifically, it is unclear whether 
MuRF1 or any E3 can act on the proteins within the myofibril, 
which is a highly organized rigid structure, or whether mecha-
nisms exist to release proteins from the sarcomeres before 
ubiquitin-dependent  degradation.  Model  studies  in  muscle 
extracts have demonstrated rapid hydrolysis of purified actin 
and myosin by the ubiquitin–proteasome pathway (Solomon 
and Goldberg, 1996). However, these proteins were much more 
stable when associated with each other in the actomyosin com-
plex or intact myofibrils. These findings raised the possibility 
that the ubiquitin–proteasome system may not by itself be able 
to  degrade  components  of  intact  myofibrils,  and  constituent 
proteins have to be released by some mechanism to be sub-
strates for degradation (Solomon and Goldberg, 1996). Conse-
quently, several groups have presented evidence that a calpain 
(Tidball and Spencer, 2002) or caspase (Du et al., 2004) may 
initially cleave the myofibrillar components, thereby accelerat-
ing disassembly and degradation by the ubiquitin–proteasome 
system. However, direct proof of these models functioning in 
atrophying muscles is lacking. Alternatively, an E3 may act 
directly on specific components of the myofibril to promote its 
disassembly and degradation during atrophy. Here, we present 
evidence for such a role for MuRF1.
Myofibrils are composed of precisely aligned filament sys-
tems arranged in repeating units of sarcomeres (Clark et al., 2002), 
whose primary constituents are myosin in the thick filament and 
actin in the thin filament. The myosin molecule comprises 50% of 
myofibrillar mass and contains two heavy chains, two regulatory 
light chains (MyLC2), and two essential light chains (MyLC1). 
These light chains bind to the globular heads of myosin, which 
comprise the cross-bridges that extend from the thick filaments to 
interact with actin and generate force through ATP hydrolysis. 
Several observations in vivo and with isolated myofibrils indicate 
that MyLC1 and MyLC2 are required for thick-filament stabiliza-
tion and normal contractility. Loss of MyLC1 or MyLC2 in 
humans (Rottbauer et al., 2006) or their homologues in zebrafish 
(Chen et al., 2008) results in a perturbation of contractility and 
a striking disorganization of the thick filaments.
In addition, the sarcomere contains many structural and 
regulatory proteins that contribute to myofibril integrity and   
stability. For example, myosin-binding protein C (MyBP-C) is 
a component of the thick filament and is distributed every 43 nm 
within the C-zone of the sarcomere, where the cross-bridges are 
found (Offer et al., 1972). Transgenic mice expressing truncated 
MyBP-C that lacks the myosin-binding site in cardiac muscle 
exhibit significant sarcomere disorganization (Yang et al., 1998). 
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nerve in the two groups of mice. 10 d later the animals were 
killed, and extracts of the gastrocnemius muscles were prepared. 
Marked induction of Myc-MuRF1 protein in these lysates 
was observed by Western blot and resembled the induction of 
MuRF1 in WT mice (Fig. 1 B). Interestingly, the content of 
Myc-R-MuRF1 in the denervated muscles was higher than the 
content of MuRF1 in WT mice (Fig. 1 D), probably because 
like many E3s, MuRF1 autoubiquitylates, and in the absence of 
the Ring-finger domain, the protein is inactive and consequently 
much more stable (Qiu and Goldberg, 2002). Even though it 
lacks the RING domain (55 amino acids), the expressed Myc-
R-MuRF1 protein was very similar in size to the endogenous 
MuRF1 because it contains a Myc tag (36 amino acids). As 
expected, the size of the Myc-MuRF1 protein was greater than 
that of the Myc-R-MuRF1 because of the presence of the 
RING domain.
To determine if MuRF1’s ubiquitin ligase activity was 
essential for atrophy and degradation of specific myofibrillar 
proteins, we analyzed the rate of denervation atrophy to learn 
if deletion of MuRF1’s Ring-finger reduced atrophy in a simi-
lar fashion as a complete MuRF1 deletion (Bodine et al., 2001). 
Unilateral atrophy of the hindlimb muscles was induced by 
cutting the right sciatic nerve in the MuRF1
/, MuRF1
myc/myc, 
and R-MuRF1
myc/myc in three separate experiments with WT 
littermates from each cohort as controls (n = 5–8). The gas-
trocnemius muscles of both limbs were dissected and weighed 
14 d later. As reported previously (Bodine et al., 2001), these 
muscles in the WT lost 35% of their mass, but only 20% in 
the MuRF1
/ (P < 0.001; unpublished data). The gastroc-
nemius muscles of mice expressing full-length Myc-MuRF1 
decreased in weight to a similar extent as in WT (36% vs. 41%, 
respectively; Fig. 1 E). In contrast, the muscles expressing the 
nonfunctional Myc-R-MuRF1 decreased in weight by only 
22% (which resembled the 20% decrease in the MuRF1
/) 
compared with the 38% decrease in WT littermates (P < 0.01; 
Fig. 1 E). Thus, MuRF1’s Ring-finger domain (i.e., its function 
as a ubiquitin ligase) is essential for rapid atrophy after de-
nervation, and loss of this domain is equivalent to the loss of the 
entire protein.
and His-ubiquitin. The His-tagged polyubiquitylated proteins 
were  purified  with  a  nickel  column,  and  mass  spectrometry 
analysis identified all of these myofibrillar proteins as species 
ubiquitylated by MuRF1 (Table I).
Generation of MuRF1 knock-in mice 
expressing MuRF1 or a MuRF1-RING 
deletion mutant
To confirm that these proteins are MuRF1’s substrates during 
atrophy in vivo, we generated two lines of knock-in mice ex-
pressing Myc epitope-tagged MuRF1, one expressing the full-
length MuRF1 (Myc-MuRF1) and a second line that expressed 
MuRF1  lacking  its  Ring-finger  domain  (Myc-R-MuRF1). 
Because the Ring-finger domain is required to catalyze ubiqui-
tylation (Hatakeyama and Nakayama, 2003), but not for inter-
action with substrates, in the Myc-R-MuRF1 strain, the proteins 
ubiquitylated by MuRF1 upon denervation should escape rapid 
degradation but still can bind to Myc-R-MuRF1, which should 
greatly facilitate their identification by mass spectrometry.   
Similar approaches have been successfully used in vitro to identify 
the substrates of other RING-finger E3s (Qiu and Goldberg, 
2002; Jang, 2004). To generate MuRF1
myc/myc and R-MuRF1
myc/myc 
mice, we engineered two targeting vectors: one that would 
result in the addition of a Myc epitope sequence at the N terminus 
of MuRF1, and one that additionally would remove the Ring-
finger domain (Fig. 1). Targeting vectors were inserted into the 
mouse genome via targeted replacement by homologous re-
combination. The heterozygous MuRF1
+/myc and R-MuRF1
+/myc 
mice were identified by real-time PCR-based loss of native 
allele (LONA) assay and were then used to generate the homo-
zygous mice used in our experiments (Fig. S2). The homozygous 
MuRF1
myc/myc and R-MuRF1
myc/myc mice showed no gross 
abnormalities and did not appear in any way different from 
either the wild-type (WT) or MuRF1
/ mice.
Effects of Myc-R-MuRF1 on  
muscle atrophy
To analyze the regulation of Myc-MuRF1 and Myc-R-MuRF1 
expression during atrophy, we sectioned unilaterally the sciatic 
Table I. MuRF1 binds a variety of myofibrillar proteins present in muscle homogenate (3,000 g supernatant)
Protein name Gene Gene ID 
(NCBI)
Precipitated from normal 
muscle with pure MuRF1
Ubiquitylated after  
addition of E1, E2,  
and ATP
Immunoprecipitated from  
denervated muscle with  
Myc-R-MuRF1
MyBP-C Mybpc2 233199 + + +
Myosin regulatory light chain 
(MyLC2)
Mylpf 17907 + + +
Myosin essential light chain 
(MyLC1)
Myl1 17901 + + +
Myosin heavy chain 1 Myh1 17879 + + +
Myosin heavy chain 4 Myh4 17884 + +
Myosin heavy chain 8 Myh8 17885 + +
Myomesin 1 Myom1 17929 + +
Actin, alpha skeletal muscle Acta1 11459 + + +
Filamin C, gamma isoform 1 Flnc 68794 + +
MuRF1-bound proteins were immunoprecipitated together with MuRF1 from gastrocnemius muscles and identified by mass spectrometry. When a subsequent in vitro 
ubiquitylation was applied, mass spectrometry analysis identified MyBP-C, MyLC 1 and 2, MyHC, actin, and myomesin as ubiquitylated species.JCB • VOLUME 185 • NUMBER 6 • 2009   1086
Figure 1.  Targeted replacement of MuRF1 with Myc-MuRF1 or Myc-R-MuRF1 and their expression in skeletal muscle after denervation. (A) Strategy for 
the generation of MuRF1
myc/myc mice showing the Ring-finger domain (gray box) spanning the first two exons of MuRF1 (endogenous locus). The targeting 
cassette was generated by replacing the firsts two exons (E1 and E2) of MuRF1 with a Myc-encoding sequence fused in-frame with the region of MuRF1 
encoding D2-S110, followed by a short intron sequence, and a selectable marker (NEO, neomycin resistance gene) (targeted locus). Upon homologous 
recombination, the floxed NEO cassette was removed with a Cre expression vector (recombined locus). (B) Immunoblot analysis of MuRF1 in gastrocnemius 
muscle from adult wild-type mice (WT) and Myc-MuRF1 from MuRF1
myc/myc littermates after 10 d of denervation. The muscles on the right hindlimb were 
denervated by cutting the sciatic nerve, and the left hindlimb muscles of each animal served as the control. A MuRF1 antibody was used for Western blot. 
Asterisks indicate nonspecific bands. (C) Strategy for the generation of R-MuRF1
myc/myc mice showing the Ring-finger domain (gray box) spanning the 
first two exons of MuRF1 (endogenous locus). The targeting cassette was generated by replacing the first two exons (E1 and E2) of MuRF1 with a Myc-
encoding sequence fused in-frame with the region of MuRF1 encoding D2-S110 without the sequence corresponding to the Ring-finger domain C23-C78, 
followed by a short intron sequence, and a selectable marker (NEO, neomycin resistance gene) (targeted locus). Upon homologous recombination, the 
floxed NEO gene was removed using a Cre expression vector (recombined locus). (D) Immunoblot analysis of MuRF1 in gastrocnemius muscle from 
WT mice and of R-Myc-MuRF1 in muscles from R-MuRF1
myc/myc littermates 10 d after denervation. Antibodies used for Western blot are indicated.   
(E) Denervation atrophy of gastrocnemius in WT and MuRF1
myc/myc or R-MuRF1
myc/myc mice. Weight of gastrocnemius in MuRF1
myc/myc animals decreased 
14 d after denervation to a similar extent as in WT littermates. By contrast, muscle weight from R-MuRF1
myc/myc animals decreased to a lesser extent than 
in WT littermates (*, P < 0.01). Weights of denervated muscles are expressed as percentage of the contralateral control. Error bars represent SEM (n = 7) 
versus innervated muscles from WT.1087 ROLE OF MuRF1 IN MYOFIBRIL DEGRADATION • Cohen et al.
total ubiquitin conjugates 10 d after denervation and probably 
for much of the increased proteolysis. The inability of muscles 
in the R-MuRF1
myc/myc mice to increase ubiquitylation can 
account for their reduced rate of atrophy.
MyLC1, MyLC2, and MyBP-C are 
selectively lost during denervation atrophy 
by a MuRF1-dependent mechanism
To clarify the role of MuRF1 in denervation atrophy and to inves-
tigate if any of these sarcomeric proteins are lost differentially 
during this process, we isolated myofibrils from gastrocnemius 
muscles, and after SDS-PAGE identified the constituent pro-
tein bands by Coomassie blue staining and mass spectrometry 
(Fig. S4 A). We then analyzed by SDS-PAGE equal amounts of 
proteins from the myofibrillar fraction of innervated and dener-
vated  muscles  from  the  MuRF1
myc/myc  and  R-MuRF1
myc/myc 
mice and measured the intensity of specific bands stained with 
Coomassie blue by densitometry (Fig. S4 B). Muscle weights in 
R-MuRF1
myc/myc  and  MuRF1
myc/myc  animals  decreased  simi-
larly (14% [P < 0.05] vs. 18% [P < 0.001], respectively) 10 d 
after denervation (unpublished data). Despite the loss of pro-
teins, the relative concentrations of the great majority of myo-
fibrillar proteins at 10 d denervation did not differ significantly 
from those in the innervated muscles (Fig. 3 A).
Surprisingly, in animals expressing Myc-MuRF1, the rel-
ative concentrations of myofibrillar MyLC2 and MyBP-C were 
markedly decreased (by 47% and 28%, respectively; P < 0.05) 
below levels the innervated controls (Fig. 3 A). By contrast, in 
R-MuRF1
myc/myc mice the relative amounts of these regulatory 
proteins did not change significantly after denervation (Fig. 3 A) 
(this decrease in the amount of MyBP-C is not due to the 
slow-to-fast change in fiber type that occurs after denervation 
[Weydert et al., 1987] because the fast and slow isoforms of 
MyBP-C have the same molecular mass and appear as one band 
on Coomassie blue–stained gels). This differential loss of 
MuRF1 has been reported to be associated with myofibrils 
(Centner et al., 2001), although an immunofluorescence study 
on cardiac myocytes detected MuRF1 also in the cytoplasm 
(McElhinny et al., 2002). After isolation of myofibrils from gas-
trocnemius muscles of the MuRF1
myc/myc, R-MuRF1
myc/myc, and 
WT mice, we found to our surprise that the great majority of 
Myc-MuRF1 and Myc-R-MuRF1 and endogenous MuRF1 in 
WT mice were in the cytosolic fraction (3,000 g supernatant) 
(Fig. S3). Therefore, if MuRF1 is in fact associated with the 
myofibrils, it is a weak, easily disrupted interaction.
To identify the MuRF1 substrates lost upon denervation   
in vivo, we immunoprecipitated Myc-R-MuRF1 from gas-
trocnemius muscles (3,000 g supernatant) from homozygous 
R-MuRF1
myc/myc mice using antibodies against its Myc tag, 
and washed the resulting immunoprecipitates as described above. 
Analysis of MuRF1-bound proteins by mass spectrometry   
identified the same set of myofibrillar proteins that were pre-
cipitated using immobilized GST-MuRF1 (Table I).
MuRF1 is responsible for most  
of the increase in ubiquitin conjugates  
after denervation
Wing et al. (1995) previously demonstrated that the muscle’s 
content of ubiquitin conjugates is significantly increased during 
denervation atrophy. We therefore examined whether this accu-
mulation of ubiquitylated proteins depends on MuRF1 function. 
In accord with prior findings on rat muscles, in mouse muscles 
expressing Myc-MuRF1 10 d after denervation, the gastroc-
nemius’s content of ubiquitin conjugates was 73% higher (P < 
0.001) than in control muscles, as shown by immunoblotting of 
the cytosolic fraction with an antibody against ubiquitin chains 
(Fig. 2). However, in R-MuRF1
myc/myc mice, a much smaller 
increase (by 42%; P < 0.05) in ubiquitin conjugates was observed 
in denervated muscles than in controls (Fig. 2). Thus, MuRF1’s 
ligase activity appears responsible for most of the increase in 
Figure 2.  MuRF1 is responsible for most of 
the increase in total ubiquitin conjugates dur-
ing  denervation  atrophy.  (A)  The  cytosolic 
fractions (20 µg) of 10-d denervated or control 
gastrocnemius muscles from MuRF1
myc/myc and 
R-MuRF1
myc/myc mice were subjected to immuno-
blotting with an antibody against polyubiquitin 
conjugates.  The  membrane  was  re-probed 
with anti-actin to ensure equal protein loading.   
C, control; D, denervation for 10 d. (B) Den-
sitometric analysis of Western blot presented 
in A, with mean given as arbitrary units. Error 
bars represent SEM, n = 4. #, P < 0.001 ver-
sus innervated muscles; *, P < 0.05 versus de-
nervated muscles from R-MuRF1
myc/myc mice.JCB • VOLUME 185 • NUMBER 6 • 2009   1088
We also confirmed by immunoblotting that the relative con-
centrations of myofibrillar MyHC and actin did not differ in 
the denervated and innervated muscles at this time (Fig. 3 B). 
By contrast, the content of Troponin-I, whose cardiac isoform 
is ubiquitylated by MuRF1 and degraded in cultured cardio-
myocytes (Kedar et al., 2004), was unchanged at 10 d denerva-
tion. Together, these data indicate that myofibrillar MyLC1, 
MyLC2, and MyBP-C are preferentially degraded during dener-
vation atrophy in a MuRF1-dependent mechanism, but other 
potential substrates of MuRF1 (e.g., the thin filament compo-
nent, Troponin-I) are not.
MyLC1, MyLC2, and MyBP-C are also lost 
differentially upon fasting
To determine if selective loss of regulatory proteins also occurs 
during other types of muscle wasting, we tested whether MyLC1, 
MyLC2,  and  MyBP-C  are  also  selectively  degraded  upon 
food deprivation where there is also rapid atrophy and MuRF1 
induction. Mice fasted for 2 d showed a 12% decrease in mus-
cle weight, a similar decrease in MyHC content, and a 24% 
decrease in actin content (P < 0.05) (Fig. S5 A, left). In contrast, 
MyBP-C and MyLC2 content decreased by almost 40% in these 
muscles (P < 0.001). Immunoblotting for MyLC1 confirmed a 
similar preferential loss (Fig. S5 A, right). The significant 
decrease in actin content at the second day of fasting was not 
apparent at 10 d denervation (Fig. 3 A), and thus may imply for 
the differences between disuse (e.g., denervation) and systemic 
catabolic states (e.g., fasting) in rates of muscle atrophy or sig-
naling pathways leading to degradation. In any case, the ratio of 
MyBP-C and MyLC2 to actin falls in the gastrocnemius by 2 d 
of food deprivation (Fig. S5 B). Thus, a similar selective loss of 
MyLC1, MyLC2, and MyBP-C occurs upon food deprivation 
as during denervation atrophy.
MyLC1, MyLC2, and MyBP-C (unlike 
MyHC) can be ubiquitylated in the 
actomyosin complex
To confirm that MyLC1, MyLC2, and MyBP-C are direct sub-
strates for MuRF1, we measured their ubiquitylation by recombi-
nant MuRF1 using different E2s and Western blot analysis (Fig. 4). 
MuRF1 ubiquitylated pure MyLC1 (Fig. 4 A), MyLC2 (Fig. 4 B), 
and MyBP-C (Fig. 4 C), as well as MyHC (Fig. 4 D) with the three 
E2s tested, UbcH1, UbcH5, or UbcH13/Uev1, all of which were 
previously shown to support ubiquitylation of cardiac Troponin-I 
by MuRF1 (Kim et al., 2007). Actin is mainly monoubiquitylated 
by MuRF1 and UbcH5 (Fig. S5 C), although in vivo this chain 
may be elongated by a different ubiquitin ligase, functioning as 
an E4 (Koegl et al., 1999) or by MuRF1 with a different E2 (as 
recently suggested for targets of the anaphase-promoting com-
plex [Rodrigo-Brenni and Morgan, 2007]).
Solomon and Goldberg (1996) had previously shown that 
when actin and myosin were in the myofibril or even in acto-
myosin complexes, these proteins were quite resistant to ubiquitin-
dependent proteolysis, unlike free actin or myosin (Solomon 
and Goldberg, 1996). To learn whether MuRF1 can directly 
ubiquitylate proteins in the myofibril, or whether this structure 
MyLC2 and MyBP-C is noteworthy because the concentrations 
of MyHC and actin in the myofibrils were unchanged in de-
nervated muscles from both groups.
Because MyLC1 and Troponin-I migrate similarly on 
SDS-PAGE, their concentrations could not be measured by this 
method. Instead, we analyzed their levels by immunoblotting 
(Fig. 3 B). Like MyLC2 and MyBP-C content, the level of 
MyLC1 was lower in the myofibrillar fraction of the denervated 
muscle than the innervated muscle from MuRF1
myc/myc mice   
but did not decrease in R-MuRF1
myc/myc animals (Fig. 3 B). 
Figure 3.  By 10 d denervation, MyLC1, MyLC2, and MyBP-C are selec-
tively lost by a MuRF1-dependent mechanism. The myofibrillar fractions 
from  10-d  denervated  and  control  gastrocnemius  muscles  from  both 
MuRF1
myc/myc  and  R-MuRF1
myc/myc  mice  were  analyzed  by  SDS-PAGE, 
Coomassie blue staining, and densitometric measurement of the specific 
bands. (A) The concentration of each protein per mg myofibrillar protein 
for denervated muscles is expressed as a percentage of the mean intensity 
in innervated controls. Error bars represent SEM, n = 3. *, P < 0.05 versus 
innervated muscles. (B) The myofibrillar fraction (0.5 µg) from denervated 
and innervated muscles from both types of mice was analyzed by SDS-
PAGE and immunoblotted with specific antibodies as indicated.1089 ROLE OF MuRF1 IN MYOFIBRIL DEGRADATION • Cohen et al.
MuRF1
myc/myc  animals,  MyLC2  and  MyBP-C  were  preferen-
tially lost (relative to actin) from the gastrocnemius by 10 d   
after denervation, whereas the relative concentration of MyHC 
was unchanged (Fig. 5 A, left). In addition, immunoblotting re-
vealed lower levels of MyLC1 in the myofibril from denervated 
muscle than in the control (Fig. 5 A, right).
A specific immunoprecipitation assay was established   
to isolate ubiquitylated proteins and analyze them by immuno-
blotting. To assay ubiquitylation of proteins in myofibrils from 
normal or denervated muscles by MuRF1, we used 6-His–tagged 
ubiquitin, UbcH1, and E1. After incubation at 37°C, 5 M urea 
was added to disassemble the myofibrils and permit efficient 
purification of the His-ubiquitylated material with a nickel   
column. When isolated myofibrils from normal mice were 
incubated with MuRF1, no significant ubiquitylation of actin or 
MyHC could be demonstrated by immunoblotting (unpublished 
data). By contrast, MyLC1, MyLC2, and MyBP-C within the 
myofibril were efficiently ubiquitylated in both control and de-
nervated muscles (Fig. 5 B). Thus, in the intact myofibril and 
even  in  the  actomyosin  complex,  MyHC  and  actin  (unlike 
MyLC1, MyLC2, and MyBP-C) show only limited susceptibil-
ity to ubiquitylation, i.e., much less than purified MyHC and 
actin. Because MyLC1, MyLC2, and MyBP-C are known to 
stabilize the thick filaments, their differential ubiquitylation and 
degradation may facilitate the ubiquitylation, disassembly, and 
degradation of other sarcomeric components.
must first be dissociated, we investigated whether MyLC1 and 
MyLC2 associated in actomyosin complexes are also substrates 
for ubiquitylation by MuRF1 (we could not measure ubiquity-
lation of MyBP-C in actomyosin because it is not present in the 
actomyosin preparation). We compared ubiquitylation of pure 
proteins and in parallel an actomyosin preparation from rabbit 
muscle (which in addition to actin, MyHCs, and MyLCs may 
contain low amounts of associated proteins, e.g., tropomyosin, 
troponin, -actinin). Similar amounts of each of the proteins 
were present in the reactions, either as pure protein or in associ-
ation  with  actomyosin  (adjusted  after  we  determined  the 
amounts of each protein by Coomassie blue staining of gels). 
MuRF1 ubiquitylated MyLC1 and MyLC2 in the actomyosin 
complex at comparable rates as the free proteins with all three 
E2s tested (Fig. 4, A and B). By contrast, MyHC could be ubiq-
uitylated only as pure protein but not when associated within 
actomyosin complex (Fig. 4 D).
MyLC1, MyLC2, and MyBP-C can also be 
ubiquitylated in the myofibril
To test whether MyLC1, MyLC2, and MyBP-C are also effi-
ciently ubiquitylated when associated within the myofibril, we 
unilaterally denervated gastrocnemius muscles from WT mice 
for 3 or 10 d, prepared myofibrils from these and the contra-
lateral normal muscles, and compared rates of ubiquitylation of 
proteins in the myofibrils by pure MuRF1. As observed in the 
Figure 4.  Pure MyLC1, MyLC2, MyBP-C, and MyHC are substrates of MuRF1, but in the actomyosin complex MyHC is not efficiently ubiquitylated. In vitro 
ubiquitylation of actomyosin complex or pure MyLC1 (A), MyLC2 (B), MyBP-C (C), and MyHC (D) by MuRF1 and three different E2s (UbcH13/Uev1). We 
assayed similar concentrations of pure MyHC and in association within actomyosin (as determined by Coomassie blue–stained gels). Asterisk indicates a 
nonspecific band. Dividing lines were used to separate top and bottom parts of the gel.JCB • VOLUME 185 • NUMBER 6 • 2009   1090
were analyzed by SDS-PAGE and Coomassie blue staining. 
Measurement of the intensity of specific bands revealed the dif-
ferential loss of MyHC from the myofibril at 14 d denervation 
in MuRF1
myc/myc mice (Fig. 6 A), which was not evident 10 d 
after denervation (Fig. 3 and unpublished data). By contrast, 
the amount of MyHC and none of the thick filaments com-
ponents (i.e., MyLC1, MyLC2, and MyBP-C) decreased in   
R-MuRF1
myc/myc animals. This slower loss of MyHC is con-
sistent with the hypothesis that the initial selective degradation 
of the thick filament–stabilizing proteins MyLC1, MyLC2, and 
MyBP-C enhances the accessibility of MyHC to ubiquitylation 
by MuRF1.
Unlike these thick filament components, at this time   
after denervation the thin filament components, actin, tropo-
myosin, and -actinin were lost from the myofibril in a similar 
fashion in the MuRF1
myc/myc and R-MuRF1
myc/myc animals 
(Fig. 6 A). Thus, although MuRF1 is required for the degrada-
tion and disassembly of the thick filaments during denervation 
atrophy, the thin filaments are degraded by a distinct mecha-
nism  that  does  not  require  MuRF1  or  MuRF1-dependent 
ubiqutiylation of other components, but may involve another 
ubiquitin ligase.
Actin and other thin filament components 
were subsequently lost independently  
of MuRF1
It has often been proposed that an initial disassembly step, 
such as a proteolytic cleavage by calpains (Goll et al., 1992) 
or caspases (Du et al., 2005) may facilitate the overall degra-
dation  of  the  myofibrillar  apparatus.  However,  we  showed 
above that MyLC1, MyLC2, and MyBP-C are preferentially 
lost  during  denervation  atrophy  by  a  MuRF1-dependent 
mechanism (Fig. 3) and can be ubiquitylated by MuRF1 when 
still associated with the myofibril (Fig. 5 B). Furthermore, 
purified soluble actin and MyHC are ubiquitylated by MuRF1 
more efficiently than when these proteins are associated with 
other components within the myofibril or even in the acto-
myosin complex (Fig. 4). These findings raise the possibility that 
the loss of MyLC1, MyLC2, and MyBP-C may enhance the 
susceptibility of other myofibrillar components to MuRF1-
dependent degradation.
To examine this hypothesis, we measured the content of 
thick  and  thin  filament  components  14  d  after  denervation. 
Control and denervated muscles from MuRF1
myc/myc and R-
MuRF1
myc/myc mice were homogenized, and isolated myofibrils 
Figure 5.  MyBP-C and MyLCs are lost selectively during atrophy and are efficiently ubiquitylated by MuRF1 in isolated myofibrils. (A) Equal amounts of the 
myofibrillar fraction from innervated gastrocnemius muscles and ones denervated for 3 or 10 d from WT mice were analyzed by SDS-PAGE and Coomassie 
blue staining (left). The intensity of specific Coomassie blue–stained bands was measured, and the ratio to actin was plotted. Error bars represent SEM, 
n = 5. *, P < 0.05. Shown on the right is Western blot analysis of myofibrillar fraction (0.5 µg, to detect MyLC1) and cytosolic fractions (20 µg, to detect 
MuRF1) from innervated and denervated muscles from WT mice. (B) MyBP-C and MyLCs are ubiquitylated by purified MuRF1 in isolated myofibrils from 
control muscles and ones denervated for 3 or 10 d using UbcH1 and His-tagged ubiquitin. His-Ubiquitylated proteins were purified with a nickel column 
and detected by immunoblotting with specific antibodies.1091 ROLE OF MuRF1 IN MYOFIBRIL DEGRADATION • Cohen et al.
Because MuRF1 is required for rapid atrophy, but not for 
normal muscle growth or function, identification of its sub-
strates is essential to understand the mechanisms of protein loss. 
We have identified a number of myofibrillar components as 
novel substrates for MuRF1 in vivo, all of which are important 
for muscle integrity and contractile activity. Mutations in each 
of  them  cause  severe  disorders  characterized  by  disarrayed 
myofibrils and compromised contractile function (Clark et al., 
2002). Although cardiac Troponin-I was previously reported to 
be a MuRF1 substrate (Kedar et al., 2004), Troponin-I could not 
be immunoprecipitated with MuRF1 from these skeletal mus-
cles and was not lost by a MuRF1-dependent mechanism after 
denervation. MyHC had been shown to accumulate in mice 
lacking MuRF1 and MuRF3 (Fielitz et al., 2007) and to be 
degraded in a MuRF1-dependent manner upon dexamethasone 
treatment of embryonic myotubes (Clarke et al., 2007). Accord-
ingly, decreased content of MyHC by a MuRFl-dependent 
mechanism was clearly evident at 14 d denervation (Fig. 6). 
However, within the myofibril from innervated muscles, MyHC 
is not ubiquitylated by MuRF1 and is not a preferred substrate 
of MuRF1 even 10 d after denervation (Fig. 3).
It is noteworthy that these various myofibrillar proteins 
could be precipitated with GST-MuRF1 from the cytosolic frac-
tion, and were ubiquitylated by pure MuRF1. Soluble pools of 
these myofibrillar components have been reported in chicken 
(Horvath and Gaetjens, 1972) and were found in the mouse 
muscle extracts (unpublished data). Possibly, these soluble com-
ponents function either as precursors to the mature contractile 
apparatus or as components released during myofibrillar turn-
over, or may represent a fraction of myofibrillar proteins that   
are easily released upon homogenization (Etlinger et al., 1975). 
However, these proteins did not accumulate in the cytosol   
Discussion
The present findings clarify the critical role that MuRF1 plays 
in muscle atrophy. Although other ubiquitin ligases are also 
induced during atrophy (i.e., atrogin-1 [Gomes et al., 2001], 
which is also essential for rapid atrophy [Bodine et al., 2001], 
as well as E3-II [Kwak et al., 2004]), MuRF1 is necessary for 
most of the increase in ubiquitin conjugates during denerva-
tion atrophy (Fig. 2). Thus, MuRF1 either ubiquitylates most 
proteins being degraded 10 d after denervation, or its actions 
allow other ligases to act. In either case, MuRF1 clearly is a 
very general ligase affecting many contractile (Table I), solu-
ble, and nuclear proteins (unpublished data), as was also sug-
gested by two-hybrid studies (Witt et al., 2005; Hirner et al., 
2008).  Moreover,  our  studies  implicate  ubiquitylation  by 
MuRF1 in the selective loss of MyBP-C, MyLC1, and MyLC2, 
as well as the slower degradation of MyHC, and thereby in the 
disassembly and degradation of myofibrillar proteins, which is 
the defining feature of the atrophy process.
Inactivation of MuRF1’s capacity to bind E2s by deletion 
of its Ring-finger motif attenuated atrophy and prevented the 
differential loss of MyBP-C, MyLC1, and MyLC2 from the 
myofibril (Fig. 3). Their selective loss is a new feature of atro-
phying muscles and seems to be of regulatory importance. Because 
these proteins appear to be critical in stabilizing the myofibril 
(see below), the reduced loss of MyHC in the R-MuRF1
myc/myc 
mice might be a direct consequence of the sparing of MyLC1, 
MyLC2, and MyBP-C. Also surprising were the findings that 
these components of the thick filaments are degraded sooner and 
by a distinct mechanism from the thin filament components, 
actin, tropomyosin, and -actinin, whose degradation is inde-
pendent of MuRF1.
Figure 6.  MyHC is lost from the myofibril by 
a  MuRF1-dependent  mechanism  14  d  after 
denervation. The myofibrillar fraction from in-
nervated muscles and ones denervated for 14 d   
from both MuRF1
myc/myc and R-MuRF1
myc/myc  
mice were analyzed by SDS-PAGE, Coomassie 
blue staining (A), immunoblotting with specific 
antibodies as indicated (B), and densitometric 
measurement of the specific bands. The con-
tent of each myofibrillar protein in denervated 
muscle is presented as percentage of levels 
in control. Error bars represent SEM, n = 3. 
*, P < 0.05 denervation versus control. #, P <   
0.05  denervation  in  MuRF1
myc/myc  versus   
R-MuRF1
myc/myc mice.JCB • VOLUME 185 • NUMBER 6 • 2009   1092
denervation, their degradation must have been accelerated much 
sooner because the loss of proteins results from the integrated 
effects of enhanced proteolysis over time. Any small changes in 
myofibrillar content (e.g., 10–20% decreases) that occur sooner 
after denervation probably cannot be detected by the methods 
used here. Accordingly, our finding that MuRF1 is induced by 3 d 
after denervation (Fig. 5 A) implies that MuRF1 functions max-
imally early in atrophy (and before any loss of myofibrillar pro-
teins is detectable). MuRF1 may promote the degradation of 
soluble cytosolic components, many of which associate with 
MuRF1 (unpublished data).
It is noteworthy that decreases in muscle mass can be 
demonstrated during the first week after denervation (Furuno 
et al., 1990) and do not seem attributable to MuRF1-dependent 
loss of myofibrillar components (Fig. 6 A). However, other E3s 
are induced rapidly during atrophy (e.g., atrogin-1) and may 
help  accelerate  degradation. Also,  recent  investigations  have 
shown that autophagy is activated rapidly during denervation-
atrophy and seems to promote destruction of mitochondria and 
cytosolic proteins, perhaps during the first week after denerva-
tion (Mammucari et al., 2007; Zhao et al., 2007; O’Leary and 
Hood, 2009), before any loss of myofibrillar myosin and actin 
can be detected.
Thus, during atrophy, MuRF1 seems to function at the ini-
tial steps of thick filament disassembly, apparently by selectively 
ubiquitylating certain key regulatory components, whose degra-
dation should facilitate the breakdown of the remaining thick 
filament components. The extraction of these ubiquitylated 
regulatory proteins from the myofibril might be directly linked to 
their degradation by the 26S proteasome, whose 19S component 
catalyzes ATP-dependent unfolding and translocation of sub-
strates into the core 20S proteasome (Smith et al., 2005). Alter-
natively, ATP-dependent extraction of these proteins may be 
catalyzed by the p97/VCP complex, which extracts ubiquitin-
conjugated proteins from ER membranes in the ER-associated 
degradation pathway (Ye et al., 2001) and plays an important 
role in myofibril assembly (Janiesch et al., 2007). Additional evi-
dence for a critical regulatory role of myofibrillar MyBP-C is 
that mRNAs for this protein also decrease selectively during 
denervation atrophy (unpublished data).
MyBP-C and MyLC2 are critical modulators of muscle 
contractility, and their loss may account for some of the altera-
tions in contractile properties seen after denervation (Zorzato 
et al., 1989; Trachez et al., 1990). Extraction of MyBP-C from 
skinned fibers leads to an increase in the Ca
2+ sensitivity of 
force development (Hofmann et al., 1991). Removal of myo-
fibrillar MyLC2 has a similar effect on the Ca
2+-tension curve as 
removal of MyBP-C. Both proteins thus appear to reduce   
inappropriate contractions by decreasing the probability of the 
myosin heads binding to actin (Moss et al., 1983). In addition, in 
heart, increasing MyBP-C content enhances the ATPase activity 
of actomyosin but not if MyLC2 was removed, and this effect 
reappeared when MyLC2 was restored (Margossian, 1985).
Several days after denervation, the muscle’s contractile 
properties change (i.e., there is a prolongation of the contraction 
and relaxation periods), apparently due to alterations in intra-
cellular concentrations of Ca
2+ (Zorzato et al., 1989) as well as 
during atrophy, when they were lost from the myofibril (un-
published data).
Although it has long been recognized that the major myo-
fibrillar proteins are degraded by the ubiquitin–proteasome 
pathway  during  atrophy  (Solomon  and  Goldberg,  1996),  the 
identification of MuRF1 as the critical ligase that acts on the myo-
fibrillar compartment (perhaps together with other E3s) suggests 
a role for ubiquitylation in disassembly of the myofibril. It is note-
worthy that purified monomeric actin and MyHC were efficiently 
ubiquitylated by MuRF1, but not when associated with each other 
in the actomyosin complex or in the intact myofibril (Fig. 4, un-
published data). Previously, Solomon and Goldberg (1996) 
demonstrated in crude homogenates that the ubiquitin–proteasome 
system rapidly degrades monomeric actin and myosin, but this 
process was not demonstrable in the extracts, when these proteins 
were associated with each other in the actomyosin complex or a 
myofibril. These early findings suggested that during atrophy a 
mechanism may exist to release these components from the myo-
fibril or to enhance the susceptibility of actin, myosin, and other 
myofibrillar proteins to ubiquitylation. However, based upon the 
present findings, it no longer seems necessary to postulate such a 
release system (see below).
MuRF1 could ubiquitylate these substrates together with 
UbcH1,  which  forms  K-48–linked  polyubiquitin  chains,  and 
UbcH13/Uev1, which forms processively K-63–linked chains, 
and UbcH5, which forms mixed chains (Kim et al., 2007) (Fig. 4). 
However, it is unclear which E2s function in proteolysis with 
MuRF1 or which types of ubiquitin chains it forms in normal or 
atrophying  muscles.  Although  K-63–linked  ubiquitin  chains 
were believed to serve functions other than proteasomal degra-
dation in vivo, recent findings indicate that K63 chains can tar-
get substrates to the proteasome in vitro and in vivo (Saeki et al., 
2009). Also, the nature and content of the E2s can influence the 
rates of protein degradation and thus the rate of atrophy.
It  is  particularly  intriguing  that  MyLC1,  MyLC2,  and 
MyBP-C are selectively degraded in a MuRF1-dependent manner 
after denervation (Fig. 3), and that these proteins, unlike MyHC 
and  actin,  are  efficiently  ubiquitylated  by  MuRF1  within  the 
myofibril (Fig. 5 B, unpublished data). Thus, these critical stabi-
lizing proteins can be substrates within the myofibril without dis-
sociation or proteolytic processing. Furthermore, the susceptibility 
of MyHC to ubiquitylation and degradation is enhanced 14 d 
after denervation (Fig. 6 A), presumably because the levels of 
MyBP-C and MyLCs in the myofibril are reduced. Accordingly, 
myosin can be extracted from the cardiac thick filament only after 
MyBP-C content has been reduced by 20% (Kulikovskaya et al., 
2007). By contrast, the thin filament components, actin, tropo-
myosin, and -actinin, were lost from the myofibril 14 d after 
denervation by a mechanism that does not require MuRF1 or the 
MuRF1-dependent loss of MyBP-C and MyLCs. However, it is 
also possible that MuRF1 may target for degradation proteins 
associated within the Z-disk lattice because Filamin C was pre-
cipitated together with MuRF1 (Table I). Alternatively, another 
E3 induced in atrophy may promote disassembly of the Z-disk 
or thin filaments, and function in the R-MuRF1 animals.
Although no reduction in the absolute levels of contractile 
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homozygous  MuRF1
myc/myc  and  R-MuRF1
myc/myc  for  all  experiments.   
Targeted replacement of MuRF1 for Myc-MuRF1 and Myc-R-MuRF1 resulted 
in the removal of the genomic sequence between the first two coding exons. 
A real-time PCR-based loss of native allele (LONA) assay using probes near 
the 5 and 3 ends of the deletion was use to screen ES cells and mouse-
tail genotyping. In addition, selected mice were genotyped by PCR using 
oligos flanking the region where the triple Myc-encoding sequence (108 
base pairs) was inserted using the oligos 5-CTGAGAGGGCCAAATCTTT-
GAGGC-3 and 5-AGCTGCTTCTCCAGGTTCTCCATAG-3.
Fractionation of muscle tissue
Mouse gastrocnemius muscles were homogenized on ice for 30 s in 19 
volumes of homogenization buffer (20 mM Tris-HCl, pH 7.2, 5 mM EGTA, 
100 mM KCl, and 1% Triton X-100), and incubated for 1 h with gentle 
agitation. After centrifugation at 3,000 g for 30 min, the supernatant (i.e., 
cytosolic fraction) was stored at 80°C. The pellet (myofibrils) was homog-
enized once in 20 volumes of homogenization buffer and twice in wash 
buffer (20 mM Tris-HCl, pH 7.2, 100 mM KCl, and 1 mM DTT). Before the 
final centrifugation (3,000 g for 10 min at 4°C) the resuspended pellet was 
filtered through a nylon cloth. The final pellet was resuspended in storage 
buffer (20 mM Tris-HCl, pH 7.2, 100 mM KCl, 1 mM DTT, and 20% glyc-
erol) and kept at 80°C. All buffers contained a protease inhibitor mix 
(10 µg/ml leupeptin, 10 µg/ml pepstatin, 3 mM benzamidine, 1 µg/ml 
trypsin inhibitor, and 1 mM PMSF). Isolated myofibrils (2.5 µg per well) 
were separated on SDS-PAGE for Coomassie blue staining.
Immunoprecipitation
The cytosolic fraction (6 mg) of gastrocnemius muscle from R-MuRF1
myc/myc 
mice was precleared with mouse IgG and Protein L-Agarose for 1 h at 4°C. 
Myc-R-MuRF1  was  immunoprecipitated  with  anti  Myc  coupled  to 
beads overnight at 4°C. In parallel, a homogenate of the gastrocnemius 
muscle from wild-type mice was precleared with immobilized GST for 1 h 
at 4°C, and then immobilized GST-MuRF1 was added for overnight incu-
bation at 4°C. Immunoprecipitated material was washed twice with each 
of the following buffers: LSB (50 mM Tris-Cl, pH 8, 0.1% Triton X-100, and 
5 mM EDTA), MSB (50 mM Tris-Cl, pH 8, 150 mM NaCl, 0.1% SDS, 0.1% 
Triton X-100, and 5 mM EDTA), and HSB (50 mM Tris-Cl, pH 8, 500 mM 
NaCl, 0.1% SDS, 1% Triton X-100, 5 mM EGTA, and 5 mM EDTA) before 
a 10-min heating at 70°C in sample buffer (Invitrogen) and 50 mM DTT.
Protein identification by mass spectrometry
Purified samples were resolved on SDS-PAGE and visualized by Coomassie 
blue. The gel was cut into eight regions, excised and subjected to in-gel 
trypsin digestion. Tryptic peptides were extracted from the gel and ana-
lyzed by liquid chromatography MS/MS (LC-MS/MS). Peptides were sep-
arated using a 37-min gradient ranging from 4 to 27% (vol/vol) acetonitrile 
in 0.1% (vol/vol) trifluoroacetic acid in a microcapillary (125 µm x 18 cm) 
column packed with C18 reverse-phase material (Magic C18AQ, 5-µm 
particles, 200 Å pore size; Michrom Bioresources) and on-line analyzed 
on The LTQ Orbitrap XL hybrid FTMS (ThermoElectron). For each cycle, one 
full MS scan acquired on the Orbitrap at high mass resolution was fol-
lowed by ten MS/MS spectra on the linear ion trap XL from the ten most 
abundant ions. MS/MS spectra were searched using the Sequest algo-
rithm against mouse NCI protein database. All peptide matches were fil-
tered based on mass deviation, Xcorr and dCorr, miscleavages, peptide 
length to get <1% false discover rate.
Immunoblotting
Cytosolic or myofibrillar fractions from gastrocnemius muscles as well as 
the in vitro ubiquitylation reactions were resolved by SDS-PAGE, trans-
ferred onto PVDF membranes, and immunoblotted with specific antibodies 
and secondary antibodies conjugated to alkaline phosphatase.
In vitro ubiquitylation assays
Ubiquitylation assays of pure proteins (1 µM MyLC, MyBP-C, or actin, and 
100 nM MyHC) and actomyosin (5 µg for MyLC and 0.13 µg for MyHC) 
were performed for 90 min at 37°C in 20-µl mixtures containing 22.5 nM E1, 
0.75 µM E2, 0.4 µM MuRF1, and 59 µM ubiquitin in reaction buffer (2 mM 
ATP, 20 mM Tris-HCl, pH 7.6, 20 mM KCl, 5 mM MgCl2, and 1 mM DTT). 
Ubiquitylation of isolated washed myofibrils (4 µg for MyBP-C, 1.11 µg for 
MyLC) was performed as described above except that His-ubiquitin was used, 
and the E2 was UbcH1 in all experiments. After incubation at 1,400 rpm for 
90 min at 37°C, myofibrils were solubilized by the addition of 12.5 µl of 1.6x 
solubilization solution (0.8 M KCl, 80 mM Tris, 0.16 mM MgCl2, 16 mM ATP, 
and 8 M Urea, pH 8) per 20-µl reaction and incubated for 30 min at 4°C 
an increased myofibrillar Ca
2+ sensitivity (Trachez et al., 1990). 
As noted above, extraction of MyBP-C or MyLC2 also leads to 
increased myofibrillar sensitivity to Ca
2+. Because Ca
2+ is less 
efficiently  pumped  out  of  the  cytosol  of  denervated  muscle 
(Finol et al., 1981), the selective loss of these regulatory compo-
nents might contribute to their altered contractile properties. 
Another characteristic of atrophied muscle is a progressive 
reduction in the twitch force. Because MyLC1 is required for 
full force production by muscle myosin (VanBuren et al., 1994), 
its selective loss (as well as subsequent loss of MyHC) should 
contribute to the loss of tension after denervation.
Although the ubiquitylation on the myofibril and selective 
degradation of the critical stabilizing proteins MyBP-C, MyLC1, 
and MyLC2 by MuRF1 is an attractive new mechanism for loss 
of the thick filaments, it remains to be proven that these sequen-
tial steps are essential for the loss of MyHC and rapid atrophy. 
It will also be important to establish the nature of the subse-
quent steps, which lead to a loss of thin filaments during   
atrophy  and  also  during  the  slower  turnover  of  myofibrillar 
components in normal muscle. This mechanism (ubiquitylation 
of key regulatory components in the myofibril) is very different 
from the frequent suggestion that the initial attack on the con-
tractile apparatus is by endoproteases, such as caspases (Du 
et al., 2004) or calpains (Tidball and Spencer, 2002). Although 
such mechanisms may function in certain apoptotic conditions 
(Du et al., 2004), direct evidence that these proteases play an 
essential or primary role is lacking, and the present findings 
demonstrate  a  very  different  MuRF1-dependent  mechanism 
that appears to function in vivo at the level of the myofibril.
Materials and methods
Antibodies and materials
Anti-Myc was purchased from Santa Cruz Biotechnology, Inc., anti-ubiquitin 
(clone  FK2)  from  Biomol,  anti-MyHC  from  Abcam,  and  anti-actin  from 
Sigma-Aldrich. Anti-MyLC2 (developed by Donald A. Fischman) and anti-
MyLC1 (developed by Frank E. Stockdale) were obtained from Develop-
mental  Studies  Hybridoma  Bank  under  the  auspices  of  the  NICHD 
(University of Iowa, Iowa City, IA). The MyBP-C antibody and the clone for 
MyBP-C  expression  in  Escherichia  coli  were  provided  by  Dr.  Marion 
Greaser (University of Wisconsin-Madison, Madison, WI). MyLC, MyHC, 
actin, and actomyosin were purchased from Sigma-Aldrich. The MuRF1 
antibody was raised against rat MuRF1 and was described previously by 
Bodine et al. (2001). UbcH1 and UbcH13/Uev1 E2-conjugating enzymes 
were purchased from Boston Biochem. UbcH5 clone for expression in 
E. coli was provided by Dr. Kazuhiro Iwai (Osaka City University, Osaka-shi, 
Japan). The GST-MuRF1 construct for expression in E. coli was described 
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